Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma

Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yeon Jeong Kim, Yumi Kang, Jun Seop Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Donghyun Park, Woong-Yang Park, Minyong Kang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5919a4ecc5f74b4eb3508a869b37d47b
record_format dspace
spelling oai:doaj.org-article:5919a4ecc5f74b4eb3508a869b37d47b2021-12-02T13:34:46ZPotential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma10.1038/s41598-021-85099-42045-2322https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85099-4https://doaj.org/toc/2045-2322Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood before and after 1 month of treatment, respectively, from four patients with mRCC who received first-line ICB treatment. Variants were detected in primary tumors of 15 patients (75%) and ctDNA was detected in the plasma of 9 patients (45%). We examined the predictive role of ctDNA in four patients who received first-line ICB therapy. In two patients showing partial response, ctDNA levels decreased after 1 month of ICB treatment. However, in one patient who showed disease progression, ctDNA levels increased after 1 month of ICB treatment. Taken together, ctDNA detection in plasma by targeted deep sequencing was feasible in patients with RCC. Moreover, the levels of ctDNA could be an early predictor of treatment response in patients with mRCC who receive ICB therapy.Yeon Jeong KimYumi KangJun Seop KimHyun Hwan SungHwang Gyun JeonByong Chang JeongSeong Il SeoSeong Soo JeonHyun Moo LeeDonghyun ParkWoong-Yang ParkMinyong KangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yeon Jeong Kim
Yumi Kang
Jun Seop Kim
Hyun Hwan Sung
Hwang Gyun Jeon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Donghyun Park
Woong-Yang Park
Minyong Kang
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
description Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood before and after 1 month of treatment, respectively, from four patients with mRCC who received first-line ICB treatment. Variants were detected in primary tumors of 15 patients (75%) and ctDNA was detected in the plasma of 9 patients (45%). We examined the predictive role of ctDNA in four patients who received first-line ICB therapy. In two patients showing partial response, ctDNA levels decreased after 1 month of ICB treatment. However, in one patient who showed disease progression, ctDNA levels increased after 1 month of ICB treatment. Taken together, ctDNA detection in plasma by targeted deep sequencing was feasible in patients with RCC. Moreover, the levels of ctDNA could be an early predictor of treatment response in patients with mRCC who receive ICB therapy.
format article
author Yeon Jeong Kim
Yumi Kang
Jun Seop Kim
Hyun Hwan Sung
Hwang Gyun Jeon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Donghyun Park
Woong-Yang Park
Minyong Kang
author_facet Yeon Jeong Kim
Yumi Kang
Jun Seop Kim
Hyun Hwan Sung
Hwang Gyun Jeon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Donghyun Park
Woong-Yang Park
Minyong Kang
author_sort Yeon Jeong Kim
title Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
title_short Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
title_full Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
title_fullStr Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
title_full_unstemmed Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
title_sort potential of circulating tumor dna as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b
work_keys_str_mv AT yeonjeongkim potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT yumikang potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT junseopkim potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT hyunhwansung potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT hwanggyunjeon potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT byongchangjeong potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT seongilseo potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT seongsoojeon potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT hyunmoolee potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT donghyunpark potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT woongyangpark potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
AT minyongkang potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma
_version_ 1718392736357285888